Hydrocephalus Market

Global hydrocephalus market was valued at $6907.5 million in 2020 and is projected to reach $10178.6 million by 2030, registering a CAGR of 4.0% from 2021 to 2030. 

The impact of COVID-19 pandemic is expected to remain moderate for the global hydrocephalus market. The companies are facing a setback, owing to the lockdown, which led to a drop in the manufacturing and the patient flow reduced substantially. However, this deleterious impact is expected to be compensated by the increase in demand for advanced programmable shunts for treating hydrocephalic patients worldwide. Likewise, the introduction of disruptive technologies such as “eShunt system” is all set to booster the growth of the hydrocephalus market post-pandemic.

Hydrocephalus is defined as a condition in which the cerebrospinal fluid (CSF) gets accumulated in the brain. It is the abnormal buildup of fluids in the cavities deep within the brain. Hydrocephalus is one of the most common reasons for brain surgery in young children. As per the data published by the Hydrocephalus Organization, hydrocephalus is a neurological disorder that affects 1 out of 770 new-born and 1 out of 100 senior citizens in America. More than 1 million Americans are currently living with this chronic condition. Moreover, in the U.S., every 15 minutes a brain surgery related to hydrocephalus is performed. 

Growth of the global hydrocephalus market is majorly driven by increase in the prevalence of neurological disorders, such as brain tumors, spinal cord injury, and stroke, are more prone to develop hydrocephalus and drive the growth of the market. Approximately 125,000 people in the U.S. are currently living with cerebrospinal fluid shunts, as per the University of California, Los Angeles Health Organization. Moreover, the National Institute of Neurological Disorders and Stroke, in 2020, stated that 1 to 2 of every 1000 babies is born with hydrocephalus globally. These aforementioned statistics represent the rise in the prevalence of hydrocephalus across the globe.

There is an ongoing trend of introducing advanced technology for hydrocephalus market in the developed economies such as the U.S. and Canada and then unveiling it to the rest of the world. For instance, in January 2021, CereVasc, engaged in the development of minimal invasive treatment for neurological disorder, announced the eShunt device which is used as a minimal invasive treatment of hydrocephalus. This propels the demand for advanced technique in the treatment of hydrocephalus which further supplements the growth of the market.

However, Shunt infections are serious complications that may lead to irreversible brain injuries, meningitis, prolonged hospital stay, increase in the use of antibiotics, and at times need for further surgeries. Similarly, malfunctions occur, owing to complete or partial blockage of shunts that interfere with their overall function. Therefore, such factors are anticipated to decrease the growth of the global hydrocephalus market during the forecast period.

Hydrocephalus Market Segmentation

The hydrocephalus market is segmented on the basis of cause, type, diagnosis, treatment, age and region. On the basis of cause, the market is categorized into congenital hydrocephalus and acquired hydrocephalus. By type, the market is segmented into communicating hydrocephalus and non-communicating hydrocephalus. The communicating hydrocephalus is categorized into normal pressure hydrocephalus, ex-vacuo hydrocephalus. The diagnosis segment is fragmented into CT scan, MRI, and ultrasound. Furthermore, on the basis of treatment, the market is categorized into surgery shunt insertion and ventriculostomy.

The age is categorized into Neonate & Pediatrics and Adults. Region-wise, the market is analyzed across North America (the U.S., Canada and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Segment Review

On the basis of cause, the market is categorized into congenital hydrocephalus and acquired hydrocephalus. The acquired hydrocephalus segment led the market in 2020, and is expected to retain its dominance during the forecast period, owing to increase in neurological disorders and injuries such as intraventricular hemorrhage, stroke, tumor, and several other types of CSF infections can result in the development of hydrocephalic conditions among patients

On the basis of type, the market is segmented into communicating hydrocephalus and non-communicating hydrocephalus. The communicating hydrocephalus is categorized into normal pressure hydrocephalus, ex-vacuo hydrocephalus. The diagnosis segment is fragmented into CT scan, MRI, and ultrasound. Furthermore, on the basis of treatment, the market is categorized into surgery shunt insertion and ventriculostomy. The age is categorized into Neonate & Pediatrics and Adults owing to a rise in the incidences of intraventricular hemorrhage or other brain injuries. Furthermore, the surge in incidences of stroke among children and adults, owing to major lifestyle changes & disorders is anticipated to boost the demand for shunts in these age groups.

North America accounted for a major share in the global hydrocephalus market in 2020, and is expected to maintain its dominance during the forecast period, owing to rise in prevalence of neurological disorder, increase in number of hydrocephalus patients, development of advanced healthcare medical devices, and development in technology for hydrocephalus in the region.

However, Asia-Pacific is expected to register highest CAGR of 5.0% from 2021 to 2030, owing to increase in geriatric population as they are more prone to neurological disorders, rise in awareness regarding minimally invasive surgeries, surge in cases of stroke and CSF related disorders and technological advances accelerate the growth of the hydrocephalus market during the forecast period.

Key players operating in the global hydrocephalus market include Aesculap Inc., Integra Lifesciences, Karl Storz Se And Co. Kg, Proteses Inc., Medtronic Plc. and Natus Medical Inc. Further, the service provider of hydrocephalus is Boston Children’s Hospital, Anadolu Medical Center, Helios Hospital, Texas Children's Hospital, and Children's National Hospital.

Key Benefits For Stakeholders

• The study provides an in-depth analysis of the hydrocephalus market, and the current trends and future estimations to elucidate imminent investment pockets
• It presents a quantitative analysis of the market from 2021 to 2030 to enable stakeholders to capitalize on the prevailing market opportunities
• Extensive analysis of the market based on procedures and services assists to understand the trends in the industry
• Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market

 Hydrocephalus Market Report Highlights